

## IFPMA 'Generation Gavi' Manifesto Report Key messages

**\*\*Confidential for internal distribution only - Last updated 20.05.2020\*\***

---

### Overview

The following key messaging framework is an internal document intended to support communications around the Gavi replenishment campaign and financing conference taking place on 4<sup>th</sup> June 2020.

---

### Short narrative

Industry's twenty-year partnership with Gavi, the Vaccine Alliance, has been defined by impact. As a unique collaboration, the alliance has been at the forefront of combining vaccine innovation with sustained immunization in the world's poorest countries. From the near eradication of polio, to the mass distribution of the pentavalent vaccine, which offers protection to children from five major infectious diseases - to new vaccines that protect against Ebola and cervical cancer - more children have been immunized with a wider range of vaccines than at any time in history. This expertise and collaboration now sits at the centre of urgent efforts to develop and deploy safe and effective COVID-19 vaccines rapidly, equitably, and at scale.

---

### Key messages

- Over the past twenty years, industry's partnership with Gavi has helped transform the health of the world's children, with over 760 million of them more likely to survive and thrive into adulthood.
  - Today, new vaccines are protecting millions of children and their communities against infectious disease, including Ebola, malaria, typhoid, pneumonia, meningitis, polio and the human papillomavirus (HPV).
  - Industry's engagement with Gavi extends beyond the discovery and supply of life-saving vaccines, to supporting countries build strong national immunization programs that are resilient to public health emergencies such as the current global pandemic.
  - Gavi's mission continues to inspire our work and drives our commitment to protect the health of the next generation, ensuring no one is left behind.
  - As the world faces its first global pandemic in living memory, our industry is working with urgency, purpose and solidarity at the heart of their efforts, to accelerate the pace with which we develop safe and effective vaccines to protect healthcare workers, entire communities and vulnerable groups – no matter where they live.
-

## Key messages and supporting messages

**Over the past twenty years, industry's partnership with Gavi has helped transform the health of the world's children, with over 760 million of them more likely to survive and thrive into adulthood.**

- Gavi's public-private partnership model has fostered a unique collaboration between industry and global health.
- By combining sustained vaccine innovation with large-scale immunization, the alliance has helped to prevent and control a wide range of infectious diseases that have historically been the leading cause of childhood mortality, including polio, measles, rotavirus and pneumonia.
- IFPMA members currently provide thirteen vaccine formulations and presentations to Gavi countries for use in routine immunization, preventative campaigns and emergency stockpiles.

**Today, new vaccines are protecting millions of children and their communities against infectious disease, including Ebola, malaria, typhoid, pneumonia, meningitis, polio and the human papillomavirus (HPV).**

- As founding partners in the Gavi alliance, industry has made the significant and sustained investment needed to manufacture a reliable supply of existing vaccines and to develop a robust pipeline of innovative new vaccines.
- On the horizon are vaccines for the respiratory syncytial virus (RSV), typhoid, meningitis (multivalent meningitis) & polio (Hexavalent wP-IPV).
- Vaccines remain one of the most cost-effective ways to save lives and promote good health and well-being.

**Industry's engagement with Gavi extends beyond the discovery and supply of life-saving vaccines, to supporting countries build strong national immunization programs that are resilient to public health emergencies such as the current global pandemic.**

- From the roll-out of the new HPV vaccine to autonomous drone delivery, industry has supported Gavi countries to find innovative ways to ensure vaccine programs reach those most in need.
- Industry continues to work alongside global health partners to strengthen national commitments to immunization and to ensure supply security through improved long-term planning.
- Gavi, industry and other global health stakeholders have made significant investments to manufacturing, stockpiling, and system preparedness to deal swiftly with epidemics - or even new pandemic threats, such as the novel coronavirus, COVID-19.

**Gavi's mission continues to inspire our work and drives our commitment to protect the health of the next generation, ensuring no one is left behind.**

- Bring to life a new generation of vaccine solutions
- Reach the most in need and underserved
- Support the strengthening, sustainability and resilience of national immunization services
- Prepare for public health emergencies
- Partner to share capabilities, expertise and maximize the impact of life-saving vaccines

**As the world faces its first global pandemic in living memory, our industry is working with urgency, purpose and solidarity at the heart of their efforts, to accelerate the pace with which we develop safe and effective vaccines to protect healthcare workers, entire communities and vulnerable groups – no matter where they live.**

- IFPMA and its members are working at unprecedented levels and with a strong sense of urgency to develop and deploys safe and effective COVID-19 vaccines rapidly, equitably, and at scale. This is rooted in deep sense of responsibility to leave no one behind and to ensure hard fought global health progress achieved in recent decades is not reversed.
- Never have the stakes been higher. Never has the biopharmaceutical industry moved as quickly and decisively to channel innovation and mobilize knowhow in response to this pandemic.
- Records are being broken in speed and in collaboration: while it typically takes 10 to 15 years to develop a vaccine, scientists and experts in the pharmaceutical industry aim to do so within 18 months; it took a few weeks since the beginning of the pandemic for a COVID-19 vaccine candidate to enter into first-in-human trials.
- As a founding partner of the Access to COVID-19 Tools (ACT) Accelerator, our industry is working in partnership with WHO and Gavi to ensure equitable and affordable access to COVID-19 vaccines.

## Key and supporting messages with proof points

**Over the past twenty years, industry's partnership with Gavi has helped transform the health of the world's children, with over 760 million of them more likely to survive and thrive into adulthood.**

- **Gavi's public-private partnership model has fostered a unique collaboration between industry and global health.**
  - IFPMA and its members are founding partners of Gavi, the Vaccine Alliance with permanent board seats to ensure effective and strategic collaboration.
  - As Gavi have said, over the past 20 years, IFPMA and its members have nurtured Gavi's potential into something that has changed the future for hundreds of millions of people.
  - Through the alliance, [Gavi estimates](#) that more children have been immunized with a wider range of vaccines than at any time in history.
- **By combining sustained vaccine innovation with large-scale immunization, the alliance has helped to prevent and control a wide range of infectious diseases that have historically been the leading cause of childhood mortality, including polio, measles, rotavirus and pneumonia.**
  - In 2001, Gavi began making the [liquid pentavalent vaccine](#) (offering protection to children from five major infectious diseases) as part of routine immunization programs; by 2018, more than 467 million children had been immunized.
  - Gavi estimates that the [rotavirus vaccine](#), which protects against the deadliest form of diarrhoea in young children, has protected more than 100 million children. There are now 45 Gavi-supported countries using cost-effective rotavirus vaccines to safeguard children.
  - Since 1988, IFPMA members have been a key partner in the Global Polio Eradication Initiative (GPEI) and supported the roll-out of vaccines to children around the world. Through significant research breakthroughs, IFPMA members have developed inactivated polio vaccines (IPV) to supplement and eventually replace live oral polio vaccines (OPV). The upcoming wP-IPV hexavalent combination vaccine will support the achievement of the polio endgame.
  - Since 2007, with the support of Gavi, 183 million children have received [pneumococcal conjugate vaccine \(PCV\)](#), which protects against the leading cause of pneumonia.
- **IFPMA members currently provide thirteen vaccine formulations and presentations to Gavi countries for use in routine immunization, preventative campaigns and emergency stock-piles.**
  - IFPMA members have developed and scaled new combination, liquid and heat stable vaccines and transformed the supply chain over the last 20 years. This innovation has improved coverage and equity and extended the benefits of immunization to those who need it most.
    - Sanofi Pasteur has developed a [controlled temperature chain \(CTC\)](#) for the cholera vaccine that allows it to reach the last mile.
    - Pfizer has developed a [multi-dose vial \(MDV\)](#) for its pneumococcal vaccine that significantly reduces storage requirements and shipping costs.
    - GSK has developed a [new four-dose vial presentation](#) of its pneumococcal vaccine to help address cold-chain challenges and a new blow-fill-seal technology to deliver compact, single dose rotavirus vaccines. 32
  - The [Advance Market Commitment](#) has accelerated uptake of new innovative vaccines, protecting millions of children against pneumococcal disease.
  - Gavi's rising support for industry's expanding portfolio of vaccines has enabled countries to build the capacity needed to [conduct over 400 vaccine introductions](#) and campaigns and contain numerous disease outbreaks.

Today, new vaccines are protecting millions of children and their communities against infectious disease, including Ebola, malaria, typhoid, pneumonia, multivalent meningitis, polio and the human papillomavirus (HPV).

- **As founding partners in the Gavi alliance, industry has made the significant and sustained investment needed to manufacture a reliable supply of existing vaccines and to develop a robust pipeline of innovative new vaccines.**
  - New vaccines are helping control the spread of the deadly [Ebola virus with 1 licensed vaccine](#) and a further 7 vaccine candidates.
  - [New malaria vaccines](#) are averting millions of deaths every year.
  - HPV vaccines are protecting a generation from HPV related diseases, including cervical cancer.
    - IFPMA members, MSD and GSK, have developed [HPV vaccines](#) that protect against 70%-90% of cervical cancer cases.
- **On the horizon are vaccines for the respiratory syncytial virus (RSV), typhoid, meningitis (multivalent meningitis) & polio (Hexavalent wP-IPV).**
  - The upcoming wP-IPV Hexavalent combinations vaccines will support the achievement of the polio endgame.
  - As a long-standing partner in the fight for the prevention and epidemic control of meningitis, IFPMA members are supporting the implementation of the “[Defeating Meningitis 2030 Roadmap](#)” through the development, manufacture and supply of innovative conjugated and multivalent vaccines.
- **Vaccines remain one of the most cost-effective ways to save lives and promote good health and well-being.**
  - Taking into account healthcare costs, lost wages and productivity due to illness, as well as the broader benefits of people living longer, healthier lives, [there is US\\$ 54 returned on every US\\$ 1 invested in immunization in Gavi-supported countries](#).
  - By preventing illness, death and long-term disability, Gavi-supported vaccines have helped [generate more than US\\$ 150 billion in economic benefits](#) between 2000 and 2017

**Industry’s engagement with Gavi extends beyond the discovery and supply of life-saving vaccines, to supporting countries build strong national immunization programs that are resilient to public health emergencies such as the current global pandemic.**

- **From the roll-out of the new HPV vaccine to autonomous drone delivery, industry has supported Gavi countries to find innovative ways to ensure vaccine programs reach those most in need.**
  - [MSD established a grant program](#) to help communities in low income countries design, implement, and evaluate HPV vaccination programs with the goal of developing a successful adolescent immunization model. In Bhutan and Rwanda, each country successfully completed a national roll-out of school-based vaccination programs, with each achieving greater than 90% vaccine coverage in their first year.
  - [GSK, working with Gavi](#), has distributed 1.9 million doses of its HPV vaccine, dramatically reducing the risk of cervical cancer for some 855,000 girls in Cambodia, São Tomé and Zimbabwe by preventing HPV infection.
  - In partnership with the International Rescue Committee (IRC) and Google, the Pfizer Foundation has run the [mReach program](#). A technology enabled platform that enables healthcare workers to identify children who require follow-up regarding immunizations. During the two-year project implementation period in Uganda, a total of 12,949 (74%) out of 17,454 children under the age of one were immunized as a result of project activities.
  - [Pfizer has also teamed up with Zipline](#), Gavi, the Bill and Melinda Gates Foundation and the UPS Foundation to support the Government of Ghana in establishing a medical drone delivery system to ensure access to routine vaccines and essential medicines in some of the country’s most hard to reach areas.
  - [GSK has contributed GBP £1.2 million to the STEP program](#), which builds skills among local immunization supply chain managers in Gavi countries, and has, since 2019, committed GBP £1.5 million over three years to a GSK-Save the Children partnership focused on strengthening immunization programs in the Somali region of Ethiopia.

- Johnson & Johnson has also supported the STEP program by enabling supply chain experts from the company to train local supply chain managers in several Gavi countries.
- The transfer of vaccine technology to those institutions able to support its successful roll-out is also helping to reach the countries and communities who need it most.
  - For example, [GSK's candidate vaccine against TB](#) is the first in more than a century to demonstrate substantial protection against the disease and is now licensed to the Bill & Melinda Gates Medical Research Institute (MRI) for further development. If successful, this vaccine could help save millions of lives globally. Similarly, in 2013, GSK transferred a new typhoid vaccine to Biological E Ltd. Having already received market authorization from the Indian Health Regulatory Agency, if approved by the WHO, the vaccine will be eligible for use in endemic regions under the GAVI umbrella.
  - Sanofi Pasteur has also performed several industrial technology transfers to vaccine manufacturers in middle-income countries (MICs). These transfers help build local capacities and respond to domestic vaccine needs such as ex IPV [Bio-pharma](#) and the hexavalent vaccine in South Africa.
- **Industry continues to work alongside global health partners to strengthen national commitments to immunization and to ensure supply security through improved long-term planning.**
  - The goal of sustainable vaccination should be a progressive transition from Gavi support towards fully self-sufficient, country adapted and evidenced-based immunization programs for countries.
  - Maintaining and strengthening national commitments to immunization is critical to protecting and advancing the health of people around the world, particularly for those communities currently underserved.
  - Sustained immunization programs are central to achieving Gavi's mission, but also the goals of the new Immunization Agenda 2030 and the Sustainable Development Goals.
  - Through multi-partner platforms, IFPMA and industry, provide technical assistance and build capacity around the manufacturing and forecasting processes needed to supply vaccines in the right amounts at the right time. Improving procurement capacity, demand predictability and volume commitments is key to improving the sustainability of immunization programs.
- **Gavi, industry and other global health stakeholders have made significant investments to manufacturing, stockpiling, and system preparedness to deal swiftly with epidemics - or even new pandemic threats, such as the novel coronavirus, COVID-19.**
  - [Through stockpiling](#), industry members manufacture, reserve and make available vaccine doses in case of outbreaks including for yellow fever, cholera, meningitis and other diseases.
  - [Gavi estimates](#) that between 2006 and 2019, Gavi-supported stockpiles helped immunize more than 90 million people.
    - For example, due to the recent outbreak of the Ebola virus in the Democratic Republic of the Congo (DRC), Gavi increased the global emergency stockpile of Ebola vaccines to 500,000 doses, up from 300,000 doses.
    - In addition, IFPMA members have been long standing partners been a long standing partner for epidemic preparedness, contributing to the WHO's stockpile of meningococcal disease, yellow fever and cholera vaccines since 2004 .
  - Since 2017 and the creation of the Coalition for Epidemic Preparedness and Innovations (CEPI), industry has shared vaccine R&D experience and expertise in a commitment to collaborate towards the development of vaccines for unmet needs.
  - Industry welcomes the quick leadership of the WHO and Gavi in providing guidance on managing and protecting immunization services during national responses to the COVID-19 virus.

**Gavi's mission continues to inspire our work and drives our commitment to protect the health of the next generation, ensuring no one is left behind.**

- Bring to life a new generation of vaccine solutions
- Reach the most in need and underserved
- Support the strengthening, sustainability and resilience of national immunization services
- Prepare for public health emergencies
- Partner to share capabilities, expertise and maximize the impact of life-saving vaccines

**As the world faces its first global pandemic in living memory, our industry is working with urgency, purpose and solidarity at the heart of their efforts, to accelerate the pace with which we develop safe and effective vaccines to protect healthcare workers, entire communities and vulnerable groups – no matter where they live.**

- IFPMA and its members are working at unprecedented levels and with a strong sense of urgency to develop and deploy safe and effective COVID-19 vaccines rapidly, equitably, and at scale. This is rooted in deep sense of responsibility to leave no one behind and to ensure hard fought global health progress achieved in recent decades is not reversed.
- Never have the stakes been higher. Never has the biopharmaceutical industry moved as quickly and decisively to channel innovation and mobilize knowhow in response to this pandemic.
- Records are being broken in speed and in collaboration: while it typically takes 10 to 15 years to develop a vaccine, scientists and experts in the pharmaceutical industry aim to do so within 18 months; it took a few weeks since the beginning of the pandemic for a COVID-19 vaccine candidate to enter into first-in-human trials.
- As a founding partner of the Access to COVID-19 Tools (ACT) Accelerator, our industry is working in partnership with WHO and Gavi to ensure equitable and affordable access to COVID-19 vaccines.